PDGFR-β mediated growth failure in pediatric CML cases on Imatinib

PDGFR-β mediated growth failure in pediatric CML cases on Imatinib

Bibliographic Details
Main Authors:	Prakamya Gupta, Pinaki Dutta
Format:	Article
Language:	English
Published:	Elsevier 2020-09-01
Series:	Pediatric Hematology Oncology Journal
Subjects:	Chronic myeloid leukemia (CML) Growth hormone (GH) Growth retardation Imatinib PDGFR-β
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468124520300504

Similar Items

Survival of Patients with CML on Imatinib Experience with 44 Iraqi Patients
by: Ali M. Jawad, et al.
Published: (2008-10-01)

Imatinib Ameliorated Retinal Neovascularization by Suppressing PDGFR-α and PDGFR-β
by: Lingli Zhou, et al.
Published: (2018-07-01)

HIF2-α Expression in CML Patients Receiving Hydroxyurea Prior to Imatinib That Achieved Major Molecular Response (MMR) versus in Those Not Achieving MMR
by: Rinaldi I, et al.
Published: (2024-02-01)

Nilotinib after resistance to imatinib in CML patients with Wolf-Parkinson White syndrome
by: Massimo Breccia
Published: (2015-10-01)

Efficacy of nilotinib therapy in patient with CML diagnosed in pre-TKI era and resistant to imatinib
by: Ivana Pierri, et al.
Published: (2015-10-01)

Activation of PDGFr-β Signaling Pathway after Imatinib and Radioimmunotherapy Treatment in Experimental Pancreatic Cancer
by: Elizabeth Mack, et al.
Published: (2011-05-01)

Efficacy of nilotinib in a young patient with high Sokal risk CML Ph+ in treatment failure after high dose imatinib
by: Sabina Russo, et al.
Published: (2015-10-01)

Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: A Study from the International Registry of Childhood CML
by: Frédéric Millot, et al.
Published: (2021-08-01)

Bullous Pemphigoid Occurring after Stopping Imatinib Therapy of CML: Is a Continuation of Post-Treatment Follow-Up Needed?
by: Alexander Yakobson, et al.
Published: (2023-09-01)

Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
by: Anna Kreutzman, et al.
Published: (2019-09-01)

Modulating retinoid-X-receptor alpha (RXRA) expression sensitizes chronic myeloid leukemia cells to imatinib in vitro and reduces disease burden in vivo
by: Bharathi M. Rajamani, et al.
Published: (2023-05-01)

Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
by: Gholamreza Bahoush, et al.
Published: (2009-07-01)

Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
by: Gholamreza Bahoush, et al.
Published: (2009-09-01)

IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW
by: Tomasz Sacha
Published: (2013-12-01)

Evaluation of Imatinib adherence in chronic myeloid leukemia patients in Babylon Province, Iraq
by: Athmar Kadhim Gatea, et al.
Published: (2023-01-01)

Serious Skin Reaction Associated with Imatinib in a Patient with Chronic Myeloid Leukemia
by: Murat Albayrak, et al.
Published: (2011-12-01)

Curcumin Decreases Viability and Inhibits Proliferation of Imatinib-Sensitive and Imatinib-Resistant Chronic Myeloid Leukemia Cell Lines
by: Esma Bilajac, et al.
Published: (2022-12-01)

Nilotinib after imatinib failure
by: Luca Pezzullo
Published: (2015-10-01)

Imatinib Sets Pericyte Mosaic in the Retina
by: Tamás Kovács-Öller, et al.
Published: (2020-04-01)

Vaccination With Live Attenuated Vaccines in Four Children With Chronic Myeloid Leukemia While on Imatinib Treatment
by: Claudia Bettoni da Cunha-Riehm, et al.
Published: (2020-04-01)

The Role of STAT5 in Tyrosine Kinase Inhibitor (IMATINIB) Resistance in CML Patients
by: Anastasia Putri, et al.
Published: (2019-10-01)

Achieving optimal response at 12 months is associated with a better health-related quality of life in patients with chronic myeloid leukemia: a prospective, longitudinal, single center study
by: Lu Yu, et al.
Published: (2018-08-01)

Efficacy of nilotinib in a patient in late chronic phase CML, intolerant to imatinib and resistant to dasatinib
by: Emilio Usala
Published: (2015-10-01)

Tyrosine Kinase Inhibitors in pediatric chronic myeloid leukemia: a focused review of clinical trials
by: Fateen Ata, et al.
Published: (2023-12-01)

EARLY MOLECULAR RESPONSE WITH IMATINIB THERAPY IN CHRONIC MYELOID LEUKEMIA AND ITS ASSOCIATION WITH BASELINE WHITE BLOOD CELL COUNT AND SPLEEN SIZE
by: Abdul Ali Wajid, et al.
Published: (2018-10-01)

Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment
by: Monika Jaruskova, et al.
Published: (2017-04-01)

Does thyroid dysfunction happen in CML patients receiving Imatinib for treatment?
by: Hossein Rahimi, et al.
Published: (2015-04-01)

Does thyroid dysfunction happen in CML patients receiving Imatinib for treatment?
by: Hossein Rahimi, et al.
Published: (2015-01-01)

Investigation of the Effect of Imatinib and Hydroxyurea Combination Therapy on Hematological Parameters and Gene Expression in Chronic Myeloid Leukemia (CML) Patients
by: Esraa K. Al-Amleh, et al.
Published: (2022-08-01)

OUR EXPERIENCE WITH TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH IMATINIB MESYLATE
by: Mojca Modic, et al.
Published: (2004-12-01)

Is imatinib still the best choice as first-line oral TKI
by: Shweta Bansal
Published: (2014-01-01)

Evaluation of the Safety of Imatinib Mesylate in 200 Iraqi Patients with Chronic Myeloid Leukemia in the Chronic Phase: Single-Center Study
by: Bassam Francis Matti, et al.
Published: (2013-12-01)

Imatinib mesylate treatment for platelet-derived growth factor receptor alfa-positive choroid plexus carcinoma
by: Chihiro Kawakami, et al.
Published: (2012-05-01)

p53 Gene (NY-CO-13) Levels in Patients with Chronic Myeloid Leukemia: The Role of Imatinib and Nilotinib
by: Hayder M. Al-kuraishy, et al.
Published: (2018-01-01)

Cytotoxicity of Isoxazole Curcumin Analogs on Chronic Myeloid Leukemia-Derived K562 Cell Lines Sensitive and Resistant to Imatinib
by: Giordana Feriotto, et al.
Published: (2023-01-01)

Chronic Myeloid Leukemia with Variant Chromosomal Translocations: Results of Treatment with Imatinib Mesylate
by: Rohan Bhise, et al.
Published: (2013-01-01)

The role of miRNA -150 between different BCR-ABL p210 transcript levels and between different levels of imatinib optimal response in CML patients
by: Kawthar Ali Radhi, et al.
Published: (2023-03-01)

Imatinib Use in Pregnancy
by: Michael J Webb, et al.
Published: (2012-12-01)

Imatinib Mesylate Treatment in Chronic Myeloid Leukemia
by: Demet Çekdemir, et al.
Published: (2020-03-01)

O tratamento da Leucemia Mielóide Crônica com mesilato de imatinibe Therapy of Chronic Myeloid Leukemia with imatinib mesylate
by: Vaneuza M. Funke, et al.
Published: (2008-04-01)